Glaucoma and cancer are connected in several ways, though the relationship is more complex than a simple cause-and-effect in either direction. Large population studies show that people with glaucoma face a modestly higher overall risk of developing cancer, certain tumors growing inside the eye can trigger glaucoma directly, and some cancer treatments damage ocular structures in ways that raise eye pressure. On top of all that, the two diseases share molecular machinery at the cellular level, and some glaucoma medications have shown intriguing activity against cancer cells in laboratory settings. The connection, in other words, runs along multiple tracks at once.
A Slightly Higher Cancer Rate in People With Glaucoma
A nationwide population-based cohort study in South Korea tracked thousands of people with glaucoma alongside matched controls and found that the overall cancer incidence rate was about 12.2 per 1,000 persons in the glaucoma group, compared with roughly 11.6 per 1,000 in controls. After adjusting for age, sex, diabetes, smoking, and body mass index, the glaucoma group still had a roughly 5 percent higher hazard of developing cancer overall.1PubMed Central. Risk of cancer in patients with glaucoma: A nationwide population-based cohort study A 5 percent bump is real in statistical terms but small in absolute terms. It does not mean glaucoma “causes” cancer. The two conditions share risk factors like older age, chronic inflammation, and oxidative stress, so what looks like a direct link may partly reflect a common background of aging biology. Still, the finding is consistent enough across analyses that researchers consider it worth exploring further rather than dismissing as noise.
When a Tumor Inside the Eye Causes Glaucoma
The most direct and clinically urgent connection between cancer and glaucoma is physical: a tumor growing inside the eye can block the drainage pathways that keep eye pressure in check. Uveal melanoma, the most common primary intraocular malignancy in adults, is the classic example.2PubMed Central. Malignant melanoma complicated with cataract and secondary glaucoma: A case report When a melanoma arises on the iris or ciliary body, the tumor itself can physically invade the angle where aqueous humor normally drains, causing pressure to climb. The same mechanism applies to metastatic deposits that land inside the eye from cancers elsewhere in the body. A classic study of eyes with intraocular tumors found that tumor invasion of the drainage angle was the most common mechanism of elevated eye pressure for both iris melanomas and ciliary body metastases.3PubMed. Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors
Tumors do not always raise eye pressure by physically plugging the drain. Some shed cells, pigment, or inflammatory debris that clogs the trabecular meshwork indirectly. Others trigger neovascularization, where abnormal new blood vessels grow across the drainage angle and seal it shut. The end result is the same: secondary glaucoma that will not respond to standard pressure-lowering drops until the underlying tumor is addressed.
Tumors That Masquerade as Ordinary Glaucoma
One of the more unsettling aspects of this connection is misdiagnosis. Because the elevated eye pressure looks and feels like garden-variety glaucoma, an intraocular tumor can hide in plain sight. A study reviewing cases referred to a glaucoma clinic found ten patients with unsuspected intraocular tumors who had been initially diagnosed with primary glaucoma or non-tumor-related secondary glaucoma. The referral diagnoses included neovascular glaucoma in six cases, congenital glaucoma in three, and angle-closure glaucoma in one.4PubMed. Glaucoma as the presenting sign of intraocular tumors: beware of the masquerading sign In other words, these patients were being treated for the wrong problem, sometimes for extended periods, while a malignancy grew undetected.
The practical takeaway here matters: if you have unexplained unilateral glaucoma, if your eye pressure is unusually resistant to treatment, or if other features do not quite fit the standard picture, a thorough dilated exam looking for a hidden mass is warranted. Clinicians who specialize in ocular oncology emphasize that cataracts and glaucoma presenting together in a middle-aged person should prompt an evaluation for an intraocular lesion as a possible primary cause.2PubMed Central. Malignant melanoma complicated with cataract and secondary glaucoma: A case report This is not common, but when it happens, catching it early changes the prognosis dramatically.
Cancer Treatments That Can Trigger Glaucoma
The connection also runs in the opposite direction: treating cancer can sometimes cause or worsen glaucoma. Radiation therapy is the best-documented culprit. When radiation is delivered near the eye for head-and-neck cancers or for eye tumors themselves, it can damage retinal blood vessels. That damage triggers the growth of abnormal new vessels, which in turn can cause neovascular glaucoma, one of the most aggressive and difficult-to-treat forms of the disease. A review of glaucoma following ionizing radiation found evidence that neovascular glaucoma tends to appear within a few years of high-dose exposure, with a threshold of at least 5 Gy and possibly much higher before the risk becomes meaningful.5PubMed Central. Glaucomagenesis following ionizing radiation exposure
The vascular damage underlying this form of glaucoma is well characterized. Stereotactic radiotherapy for choroidal melanoma, for instance, has been linked to neovascular glaucoma with findings of fibrinoid necrosis and hyalinization in retinal blood vessels, hallmarks of radiation-induced vascular injury.6PubMed. Neovascular glaucoma after stereotactic radiotherapy for juxtapapillary choroidal melanoma: histopathologic and dosimetric findings A separate case report described a patient developing neovascular glaucoma three years after radiotherapy for a nasal chondrosarcoma, illustrating that the risk extends beyond tumors of the eye itself to radiation aimed at nearby structures.7PubMed. Radiation-induced neovascular glaucoma: A devastating disease
Newer immunotherapy drugs have introduced a different mechanism. Immune checkpoint inhibitors, which are now widely used for melanoma, lung cancer, and other malignancies, work by releasing the brakes on the immune system. Occasionally, the unleashed immune response attacks the eye. Case reports describe patients on PD-1 or PD-L1 inhibitors developing uveitis (inflammation inside the eye) along with elevated eye pressure. In one case, a patient on nivolumab reported blurry vision for a week before an emergency consultation revealed both a retinal detachment and glaucoma.8PubMed Central. Ocular adverse events in PD-1 and PD-L1 inhibitors Another report documented two patients who developed mild anterior uveitis and elevated eye pressure with open angles during checkpoint inhibitor treatment, attributed to presumed trabeculitis, an inflammation of the drainage tissue itself.9American Journal of Ophthalmology Case Reports. Immune checkpoint inhibitor associated ocular hypertension (from presumed trabeculitis)
These immunotherapy-related eye complications are still considered uncommon, but they are increasingly recognized. If you are on a checkpoint inhibitor and notice new visual symptoms, even mild ones, bringing them up promptly is important. The tendency to dismiss blurry vision as fatigue or a minor nuisance can delay detection of something that needs urgent attention.
Shared Molecular Machinery
Beyond the clinical overlap, glaucoma and cancer share some of the same molecular pathways at the cellular level. This does not mean one disease transforms into the other. It means that the same proteins and signaling networks that go haywire in cancer also play roles in the damage that occurs in glaucoma, particularly in how cells die and how tissues remodel.
The tumor-suppressor protein p53 is a central example. In cancer biology, p53 is famous as the “guardian of the genome,” a protein that normally pushes damaged cells toward programmed death, or apoptosis. When p53 is mutated or disabled, cells escape this checkpoint and can become cancerous. In glaucoma, the same p53 pathway is implicated in the death of retinal ganglion cells, the nerve cells whose loss causes vision damage. Research has shown that p53 activation can upregulate pro-death signals and downregulate survival signals in these cells, contributing to the progressive nerve loss that defines the disease.10PubMed. Apoptosis of retinal ganglion cells in glaucoma: an update of the molecular pathways involved in cell death So in a sense, glaucoma involves too much p53-driven cell death in the retina, while many cancers involve too little of it elsewhere in the body. The same protein, opposite problems.
Another shared player is the TGF-β signaling pathway. In the eye, TGF-β2 is implicated in changes to the trabecular meshwork, the tissue responsible for draining fluid and regulating eye pressure. Transcriptome profiling of human trabecular meshwork cells treated with TGF-β2 revealed widespread changes in genes involved in tissue remodeling, inflammation, cell proliferation and death, oxidative stress, and other pathways.11Scientific Reports. Genome-wide transcriptome profiling of human trabecular meshwork cells treated with TGF-β2 Many of these same pathways are well established in cancer biology: TGF-β signaling, MAPK signaling, and extracellular matrix regulation are all active research areas in oncology. The convergence does not prove a causal link between the two diseases, but it suggests that people whose biology tips in certain directions along these pathways may be vulnerable to both conditions.
Breast Cancer and Glaucoma
Among the specific cancer types linked to glaucoma, breast cancer has received particular attention. A presentation at a major ophthalmology research conference reported that women with a history of breast cancer were roughly three times more likely to have a diagnosis of primary open-angle glaucoma compared with women without breast cancer. Among women diagnosed with open-angle glaucoma in that study, 14 percent had a history of breast cancer, compared with only 5 percent in controls.12touchREVIEWS in Ophthalmology. Association of Breast Carcinoma with Glaucoma: A Review
The reasons for this association are not fully pinned down. Hormonal factors are one hypothesis, since estrogen receptors exist in ocular tissues and changes in estrogen levels after menopause or during cancer treatment could plausibly affect eye pressure regulation. Tamoxifen and aromatase inhibitors, commonly used in breast cancer, have known ocular side effects, though their specific role in glaucoma risk is still being studied. The association could also be partly driven by shared risk factors like age and genetics. At this point, the connection is strong enough to warrant awareness but not strong enough to change screening guidelines. Women with a breast cancer history do not need more frequent glaucoma exams based solely on this finding, but they should not skip routine eye care either.
Glaucoma Drugs With Anticancer Properties
An unexpected twist in the glaucoma-cancer story involves the drugs used to treat glaucoma. Beta-blockers like timolol are among the most commonly prescribed glaucoma medications, applied as eye drops to lower intraocular pressure. In laboratory studies, these same drugs have shown activity against cancer cells. Timolol, for instance, was tested on human prostate cancer cells and found to kill them in a concentration-dependent manner at doses between 200 and 600 micromolar, through mechanisms involving calcium signaling disruption and direct cytotoxicity.13PubMed. Effects of timolol on Ca(2+) handling and viability in human prostate cancer cells
Propranolol, a systemic beta-blocker related to timolol, has attracted even more attention in preclinical cancer research. A systematic review noted that propranolol shows activity against cancer cell proliferation, angiogenesis, and immunosuppression in laboratory settings, though clinical evidence in actual patients remains inconsistent.14Quality in Sport. Old Drugs, New Roles: Non-Cardiac Uses of Beta-Blockers – An Updated Systematic Review The gap between killing cancer cells in a dish and treating cancer in a person is enormous, and nobody is prescribing glaucoma drops as a cancer therapy. But the overlap is scientifically interesting and feeds into a broader research effort to repurpose existing drugs for new uses.
Carbonic anhydrase inhibitors, another class of glaucoma drugs, have drawn attention from a different angle. Certain carbonic anhydrase isoforms, particularly CA IX and CA XII, are overexpressed in many solid tumors and help cancer cells survive in acidic, low-oxygen environments. Compounds designed to inhibit these isoforms could theoretically serve dual purposes. One line of research explored monothiocarbamates that inhibited the glaucoma-relevant isoforms CA I and CA II as well as the tumor-associated CA IX and CA XII, and also lowered eye pressure in an animal model.15Journal of Medicinal Chemistry. Monothiocarbamates Strongly Inhibit Carbonic Anhydrases in Vitro and Possess Intraocular Pressure Lowering Activity in an Animal Model of Glaucoma This is early-stage research, but it illustrates how the biochemistry of the two diseases can overlap in unexpected and potentially useful ways.
Why the Connection Is Complicated to Study
One reason the glaucoma-cancer relationship remains poorly understood relative to its potential importance is that both diseases are strongly associated with aging. Glaucoma prevalence rises sharply after age 40, and cancer incidence climbs through every subsequent decade. Teasing apart a genuine biological connection from the simple fact that older people are more likely to have both conditions is a persistent challenge. Large cohort studies like the Korean one described earlier attempt this with statistical adjustment, but no observational study can fully eliminate confounding.
There is also a detection bias to consider. People with glaucoma see an ophthalmologist regularly, sometimes several times a year. More contact with the healthcare system means more opportunities to catch other conditions, including early-stage cancers that might otherwise go undetected for longer in someone without a chronic eye condition. Some of the modest statistical excess in cancer incidence among glaucoma patients could reflect this surveillance effect rather than a real increase in cancer occurrence.
The molecular evidence is suggestive but circumstantial. Showing that two diseases use overlapping pathways does not prove they share a cause or that one influences the other’s progression. Inflammation, oxidative stress, and dysfunctional apoptosis are features of dozens of conditions, from heart disease to neurodegeneration. The fact that glaucoma and cancer both involve these pathways could mean something specific about the relationship between the two, or it could simply reflect how a limited set of cellular stress responses manifests across many different tissues.
Practical Considerations for Patients
If you have glaucoma, nothing in the current evidence suggests you need additional cancer screening beyond what is recommended for your age and risk profile. The slightly elevated statistical risk does not rise to the level that would justify changing clinical practice. Conversely, if you are being treated for cancer, especially with radiation near the head or with immune checkpoint inhibitors, awareness that your eye pressure could be affected is useful. Report new visual symptoms to your oncology team, and do not assume that blurry vision or eye discomfort is just a minor side effect.
For people with unexplained or treatment-resistant glaucoma in one eye, the possibility that a hidden intraocular tumor is driving the pressure elevation deserves consideration. This is uncommon, but the consequences of missing it are severe enough that a careful examination for masquerading tumors is worthwhile, particularly when the clinical picture does not quite fit the usual glaucoma profile.
If you are taking beta-blocker eye drops for glaucoma and have also been diagnosed with cancer, the laboratory findings on timolol and related drugs are interesting to know about but do not mean your eye drops are treating your cancer. The concentrations used in cell studies are far higher than what reaches the bloodstream from a topical eye drop. Still, the research adds to a growing understanding that the pharmacology of glaucoma and cancer is more entangled than anyone expected a few decades ago.